How translational modeling in oncology needs to get the mechanism just right

Small Models for Big Data

(2020) Hitesh B. Mistry et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors

(2020) Cristina Vaghi et al.   PLoS Computational Biology

Opportunities for Quantitative Translational Modeling in Oncology

(2020) James W.T. Yates et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Improving the Accuracy of Predicted Human Pharmacokinetics: Lessons Learned from the AstraZeneca Drug Pipeline Over Two Decades

(2020) Michael Davies et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment

(2020) Francois Mercier et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

(2019) Richard Gray et al.   LANCET

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

(2019) Hitesh B. Mistry et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non–small Cell Lung Cancer

(2019) Ahmed Salem et al.   CLINICAL CANCER RESEARCH

Mathematical Models of Cancer: When to Predict Novel Therapies, and When Not to

(2019) Renee Brady et al.   BULLETIN OF MATHEMATICAL BIOLOGY

A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade

(2019) Oleg Milberg et al.   Scientific Reports

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

(2019) René Bruno et al.   CLINICAL CANCER RESEARCH

Chemotherapy Dose Intensity and Overall Survival Among Patients With Advanced Breast or Ovarian Cancer

(2018) Neelima Denduluri et al.   Clinical Breast Cancer

Structural identifiability for mathematical pharmacology: models of myelosuppression

(2018) Neil D. Evans et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Reproducibility of preclinical animal research improves with heterogeneity of study samples

(2018) Bernhard Voelkl et al.   PLOS BIOLOGY

Differences in predictions of ODE models of tumor growth: a cautionary example

(2016) Hope Murphy et al.   BMC CANCER

Array of translational systems pharmacodynamic models of anti-cancer drugs

(2016) Sihem Ait-Oudhia et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

The five Rs of chemotherapy

(2016) Ian F Tannock   LANCET ONCOLOGY

Toward a Science of Tumor Forecasting for Clinical Oncology

(2015) T. E. Yankeelov et al.   CANCER RESEARCH

Relationship Between Tumor Size and Survival in Non–Small-Cell Lung Cancer (NSCLC): An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Registry

(2015) Jianjun Zhang et al.   Journal of Thoracic Oncology

High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response

(2015) Hui Gao et al.   NATURE MEDICINE

Bridging the gap between in vitro and in vivo: Dose and schedule predictions for the ATR inhibitor AZD6738

(2015) Stephen Checkley et al.   Scientific Reports

Optimizing Dosing of Oncology Drugs

(2014) L Minasian et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Resistance through repopulation

(2014) Ian F. Tannock   NATURE

Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework

(2014) David Cook et al.   NATURE REVIEWS DRUG DISCOVERY

Laplace’s Demon and the Adventures of His Apprentices

(2014) Roman Frigg et al.   PHILOSOPHY OF SCIENCE

The Model Muddle: In Search of Tumor Growth Laws

(2013) P. Gerlee   CANCER RESEARCH

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

(2013) P A Milligan et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Modelling of tumour growth and cytotoxic effect of docetaxel in xenografts

(2013) Neil D. Evans et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Model-based drug discovery: implementation and impact

(2013) Sandra A.G. Visser et al.   DRUG DISCOVERY TODAY

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

(2013) Noriyuki Katsumata et al.   LANCET ONCOLOGY

Antitumor Activity of Targeted and Cytotoxic Agents in Murine Subcutaneous Tumor Models Correlates with Clinical Response

(2012) H. Wong et al.   CLINICAL CANCER RESEARCH

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies

(2011) Quinci Romero et al.   BMC CANCER

Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival

(2011) Paul Morgan et al.   DRUG DISCOVERY TODAY

Scaling rules for diffusive drug delivery in tumor and normal tissues

(2011) James W. Baish et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Prediction of Exposure–Response Relationships to Support First-in-Human Study Design

(2010) John P. Gibbs   AAPS Journal

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

(2010) Hans Wildiers et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy

(2010) Liz Y. Han et al.   EUROPEAN JOURNAL OF CANCER

Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice

(2010) Nelson L. Jumbe et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Cell cycle times of short-term cultures of brain cancers as predictors of survival

(2008) C E Furneaux et al.   BRITISH JOURNAL OF CANCER